A Multiple Part, Phase 1 Crossover Study in Healthy Subjects to Evaluate the Pharmacokinetic (PK) Profile of KVD824 Following Single and Multiple Doses of Novel KVD824 Modified Release (MR) Formulations Compared to a Reference KVD824 Immediate Release (IR) Formulation
Latest Information Update: 18 Nov 2021
At a glance
- Drugs KVD 824 (Primary) ; KVD 824 (Primary)
- Indications Diabetic macular oedema; Hereditary angioedema
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors KalVista Pharmaceuticals
- 03 Nov 2021 Status changed from recruiting to completed.
- 28 Apr 2021 New trial record
- 15 Dec 2020 According to a KalVista Pharmaceuticals media release, to date, 98 subjects have been exposed to treatment with KVD824 as single doses up to 1280 mg and up to 14 days of twice-daily dosing of 600 mg and 900 mg and there have been no concerning safety or tolerability signals. The company will release the full safety data set upon completion of the study.